0
Obstructive Lung Diseases |

QVA149 Significantly Improves Lung Function and Reduces Rescue Medication Use Compared With Its Monocomponents in COPD Patients With Moderate-to-Severe Airflow Limitation: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies

Edward Kerwin, MD; Tim Ayers; Donald Banerji; Samopriyo Maitra; Francesco Patalano
Author and Funding Information

Clinical Research Institute of Southern Oregon, Medford, OR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Healthcare Pvt Ltd, Hyderabad, India; Novartis Pharma AG, Basel, Switzerland


Chest. 2015;148(4_MeetingAbstracts):729A. doi:10.1378/chest.2276227
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters V

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: QVA149 is a dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist, indacaterol (IND) and the long-acting muscarinic antagonist, glycopyrronium (GLY), approved in over 50 countries including the EU, Japan, Mexico, Canada and Australia for maintenance treatment of COPD. The FLIGHT1 and FLIGHT2 studies compared the efficacy and safety of QVA149 (IND/GLY) with its monocomponents and placebo. Here, we present the pooled data from FLIGHT1 and FLIGHT2 studies to evaluate the superiority of IND/GLY in terms of improvement in lung function and reduction in rescue medication usage over its monocomponents and placebo.

METHODS: FLIGHT1 and FLIGHT2 were replicate, multi-center, double-blind, parallel-group, placebo- and active-controlled studies. COPD patients with moderate-to-severe airflow limitation were randomized (1:1:1:1) to IND/GLY (27.5/12.5 μg), IND (27.5 μg), GLY (12.5 μg) or placebo (all twice daily). Data on improvement in lung function in terms of FEV1 AUC0-12h and reduction in rescue medication usage with IND/GLY versus its monocomponents (IND and GLY) and placebo were pooled and analyzed.

RESULTS: In total, data of 2038 patients (IND/GLY, n=508; IND, n=511; GLY, n=511; placebo, n=508) from both the studies were pooled and analyzed. On Day 1 and at Week 12, IND/GLY significantly (p<0.001) improved FEV1 AUC0-12h with a least squares mean (LSM) treatment difference of 95 mL and 103 mL versus IND, 45 mL and 88 mL versus GLY and 171 mL and 246 mL versus placebo, respectively. Patients treated with IND/GLY used significantly less rescue medication (puffs/day) compared with placebo (LSM treatment difference: -1.20; p<0.001), IND (LSM treatment difference: -0.33; p=0.011) and GLY (LSM treatment difference: -0.50; p<0.001).

CONCLUSIONS: The IND/GLY fixed-dose combination demonstrated significant improvemnt in lung function and reduction in rescue medication usage over its monocomponents and placebo in COPD patients with moderate-to-severe airflow limitation..

CLINICAL IMPLICATIONS: These findings support the potential of IND/GLY as an alternative treatment option for COPD patients with moderate-to-severe airflow limitation.

DISCLOSURE: Edward Kerwin: Consultant fee, speaker bureau, advisory committee, etc.: Served on advisory boards, speaker panels, or received travel reimbursement for Amphastar, Astra Zeneca, Forest, Ironwood, Merck, Mylan, Novartis, Pearl, Pfizer, Sanofi Aventis, Sunovion, Targacept, Teva and Theravance. , Grant monies (from industry related sources): Conducted multicenter clinical research trials for Novartis Tim Ayers: Employee: Employee of the study sponsor, Novartis and no other conflicts Samopriyo Maitra: Employee: Employee of the study sponsor, Novartis and no other conflicts Francesco Patalano: Employee: Employee of the study sponsor, Novartis and no other conflicts Donald Banerji: Employee: Employee of the study sponsor, Novartis and no other conflicts

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Marijuana and lung diseases. Curr Opin Pulm Med 2014;20(2):173-9.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543